Garth Lees-Rolfe - 01 Apr 2024 Form 3 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	IKT	Stock Option (right to buy)							01 Apr 2024	Common Stock	5,834	$3.79	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	One-third of the options vested and became exercisable on November 28, 2023. One-third of the options will vest and become exercisable on November 28, 2024 and one-third of the options will vest and become exercisable on November 28, 2025, in each case subject to continued employment through each such vesting date.
F2	The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.